Основные параметры
P/S |
66.52 |
P/BV |
11.58 |
EV/EBITDA |
-104.03 |
EBITDA |
-0.0412 |
Цена ао |
67.84 |
Все параметры ⇨
Оценка
|
Недооценка
Название |
Значение |
Оценка |
P/S |
66.52 |
1 |
P/BV |
11.58 |
1 |
P/E |
|
0 |
EV/EBITDA |
-104.03 |
10 |
|
|
|
|
Эффективность
Название |
Значение |
Оценка |
ROA, % |
-7 |
1 |
ROE, % |
-17.57 |
1 |
|
|
|
|
|
Дивиденды
Название |
Значение |
Оценка |
Div yield, % |
|
0 |
DSI |
0 |
0 |
|
|
|
|
Долг
Название |
Значение |
Оценка |
Долг/EBITDA |
|
0 |
|
|
|
|
Импульс роста
Название |
Значение |
Оценка |
Рост прибыли, % |
0 |
0 |
Рост цены акции, % |
0 |
0 |
Рост дивидендов, % |
0 |
0 |
|
|
|
|
Основные владельцы
Institutions |
Объем |
Доля, % |
Hartford Funds Management Company, LLC |
8153493 |
11.78 |
Peroni Portfolio Advisors, Inc |
200 |
0 |
RA Capital Management, LLC |
4826910 |
6.97 |
Opaleye Management Inc |
356000 |
0.51 |
Hennion & Walsh, Inc |
100 |
0 |
Integral Health Asset Management, LLC |
185000 |
0.27 |
Cormorant Asset Management, LLC |
1400000 |
2.02 |
SV Life Sciences Managers LLP |
191600 |
0.28 |
Wells Fargo Funds Management LLC |
381197 |
0.55 |
BlackRock Fund Advisors |
4454590 |
6.44 |
Fidelity SelectCo, LLC |
5212989 |
7.53 |
Knott David M |
75033 |
0.11 |
Carmignac Gestion Luxembourg S.A. |
58396 |
0.08 |
Crow Point Partners, LLC |
1990 |
0 |
Prudential Retirement Services |
123117 |
0.18 |
Fidelity Management & Research Company LLC |
9783121 |
14.14 |
Mangrove Partners |
353219 |
0.51 |
Northern Trust Investments Inc |
942330 |
1.36 |
Morningstar |
1337621 |
1.93 |
Mason Street Advisors, LLC |
534954 |
0.77 |
Hennion & Walsh, Inc |
100 |
0 |
Blue Rock Advisors Inc |
53784 |
0.08 |
Fidelity Management & Research Company LLC |
5351027 |
7.73 |
Allianz Global Investors GmbH |
76692 |
0.11 |
Invesco Capital Management LLC |
483056 |
0.7 |
The Variable Annuity Life Insurance Company |
142011 |
0.21 |
TimesSquare Capital Management, LLC |
25370 |
0.04 |
Содержится в ETF
Похожие компании
Описание ChemoCentryx, Inc.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.